# Pulmotect, Inc.

> Pulmotect is a privately held Houston biotechnology company developing PUL-042, an experimental inhaled combination that activates innate immune defenses in the lung. Its current Phase 2 program tests whether it can reduce lower respiratory complications in patients with blood cancers or stem-cell transplants who have certain viral infections.

- **Founded:** 2007
- **Headquarters:** Houston, United States
- **Founders:** Brenton Scott (Co-founder; President and Chief Operating Officer), Burton F. Dickey (Co-founder; platform co-inventor; scientific adviser), Magnus Höök (Co-founder; inventor; board member)
- **Products:** PUL-042 Inhalation Solution
- **Notable:** Advanced university-origin lung-immunity technology into human clinical trials., Completed two randomized COVID-19 Phase 2 studies with 217 and 101 participants; the prevention trial did not show a significant primary endpoint difference., Reported favorable tolerability in more than 200 PUL-042 recipients across early trials.

## Products & services

- **PUL-042 Inhalation Solution** — Investigational combination of Pam2CSK4 and ODN M362, agonists of TLR2/6 and TLR9. Delivered by nebulization to activate innate lung defenses. Phase 2 study NCT06665100 evaluates lower respiratory complications after PIV, hMPV or RSV infection in patients with hematologic malignancies or hematopoietic stem-cell transplants. Not an approved commercial treatment.

## Achievements

- Advanced university-origin lung-immunity technology into human clinical trials.
- Completed two randomized COVID-19 Phase 2 studies with 217 and 101 participants; the prevention trial did not show a significant primary endpoint difference.
- Reported favorable tolerability in more than 200 PUL-042 recipients across early trials.
- Company reported patents issued in 28 countries in its 2025 update.
- Initiated dosing in its cancer-patient Phase 2 study in 2025.

## Latest updates

- **2026-08** — ClinicalTrials.gov record updated August 4: NCT06665100 listed recruiting, estimated enrollment 100, estimated primary completion April 2027 and study completion May 2027.
- **2025-07** — Company announced dosing had begun in the cancer-patient Phase 2 trial; release dated July 8, posted to company news July 10.
- **2025-04** — An mBio paper reported improved survival with nebulized Pam2ODN in an immunosuppressed mouse model of influenza-associated pulmonary aspergillosis; animal evidence, not human efficacy.
- **2024-09** — Announced $5.9 million Series C led by Fannin Partners with Axil Capital participation.

## Links

- Website: https://pulmotect.com/
- LinkedIn: https://www.linkedin.com/company/15321168
- Twitter/X: https://twitter.com/pulmotect

---

Profile page: https://yespress.io/pulmotect-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-15